Statement of Changes in Beneficial Ownership (4)
January 13 2021 - 5:19PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
Hippel James |
2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp
[
TECH
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Chief Financial Officer |
|
(Last)
(First)
(Middle)
614 MCKINLEY PLACE N.E. |
3. Date of Earliest Transaction
(MM/DD/YYYY)
1/11/2021 |
|
(Street)
MINNEAPOLIS, MN 55413
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
| Common Stock | 1/11/2021 | | M | | 10000 | A | $106.59 | 19137 | D | |
| Common Stock | 1/11/2021 | | S(1) | | 400 | D | $328.6809 (2) | 18737 | D | |
| Common Stock | 1/11/2021 | | S(1) | | 400 | D | $330.265 (3) | 18337 | D | |
| Common Stock | 1/11/2021 | | S(1) | | 700 | D | $331.6094 (4) | 17637 | D | |
| Common Stock | 1/11/2021 | | S(1) | | 2501 | D | $333.2328 (5) | 15136 | D | |
| Common Stock | 1/11/2021 | | S(1) | | 3990 | D | $334.3907 (6) | 11146 | D | |
| Common Stock | 1/11/2021 | | S(1) | | 2009 | D | $334.9842 (7) | 9137 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code
(Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) | 8. Price of Derivative Security
(Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Stock Options (Right to Buy) | $106.59 | 1/11/2021 | | M | | | 10000 | (9) | 8/18/2023 | Common Stock | 10000 | $0 | 49942 | D | |
| Stock Options (Right to Buy) | $125.05 | | | | | | | (9) | 8/9/2024 | Common Stock | 24460 | | 24460 | D | |
| Stock Options (Right to Buy) | $125.05 | | | | | | | (10) | 8/9/2024 | Common Stock | 32613 | | 32613 | D | |
| Restricted Stock Units | (8) | | | | | | | (11) | (11) | Common Stock | 3383 | | 3383 | D | |
| Stock Options (Right to Buy) | $177.32 | | | | | | | (11) | 8/8/2025 | Common Stock | 18066 | | 18066 | D | |
| Stock Options (Right to Buy) | $177.32 | | | | | | | (12) | 8/8/2025 | Common Stock | 24089 | | 24089 | D | |
| Restricted Stock Units | (8) | | | | | | | (13) | (13) | Common Stock | 3938 | | 3938 | D | |
| Stock Options (Right to Buy) | $190.41 | | | | | | | (13) | 8/7/2026 | Common Stock | 19936 | | 19936 | D | |
| Stock Options (Right to Buy) | $190.41 | | | | | | | (14) | 8/7/2026 | Common Stock | 26581 | | 26581 | D | |
| Restricted Stock Units | (8) | | | | | | | (15) | (15) | Common Stock | 3219 | | 3219 | D | |
| Stock Options (Right to Buy) | $267.87 | | | | | | | (15) | 8/5/2027 | Common Stock | 14360 | | 14360 | D | |
| Stock Options (Right to Buy) | $267.87 | | | | | | | (16) | 8/5/2027 | Common Stock | 19147 | | 19147 | D | |
| Stock Options (Right to Buy) | $267.87 | | | | | | | (17) | 8/5/2027 | Common Stock | 8325 | | 8325 | D | |
| Stock Options (Right to Buy) | $267.87 | | | | | | | (18) | 8/5/2027 | Common Stock | 8325.0 | | 8325.0 | D | |
| Explanation of Responses: |
| (1) | The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2020. |
| (2) | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $328.46 to $329.38, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| (3) | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $330.06 to $330.80, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| (4) | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $331.06 to $332.02, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| (5) | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $332.79 to $333.73, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| (6) | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $333.79 to $334.78, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| (7) | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $334.81 to $335.61, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| (8) | Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. |
| (9) | Fully exercisable. |
| (10) | Options to purchase 8,153 shares vest on each of 8/9/2018, 8/9/2019, 8/9/2020 and options to purchase 8,154 shares vest on 8/9/2021. |
| (11) | Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| (12) | Options to purchase 6,023 shares vest on 8/8/2019 and options to purchase 6,022 shares vest on each of 8/8/2020, 8/8/2021 and 8/8/2022. |
| (13) | Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| (14) | Options to purchase 6,646 shares vest on 8/7/2020 and options to purchase 6,645 shares vest on each of 8/7/2021, 8/7/2022 and 8/7/2023. |
| (15) | Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| (16) | Options to purchase 4,787 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023 and options to purchase 4,786 shares vest on 8/5/2024. |
| (17) | Options to purchase 2,775 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023. |
| (18) | Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021. |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
Hippel James
614 MCKINLEY PLACE N.E.
MINNEAPOLIS, MN 55413 |
|
| Chief Financial Officer |
|
Signatures
|
| /s/ Brenda S. Furlow, Attorney-in-Fact for James Hippel pursuant to Power of Attorney previously filed. | | 1/13/2021 |
| **Signature of Reporting Person | Date |
Bio Techne (NASDAQ:TECH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bio Techne (NASDAQ:TECH)
Historical Stock Chart
From Apr 2023 to Apr 2024
